Johnson & Johnson Reports ICOTYDE Psoriasis Trial Meets Main Endpoints

Johnson & Johnson reported that its ICONIC-ASCEND study of ICOTYDE (icotrokinra) met both co-primary endpoints versus placebo in moderate-to-severe plaque psoriasis. The company also reported non-inferiority to ustekinumab on key secondary skin-clearance measures, while noting that statistical superiority was not demonstrated across those endpoints. The distinction matters when interpreting the oral medicine's comparison with an injectable biologic. Johnson & Johnson News report.

What the Phase 3 ICONIC-ASCEND Study Found

According to Johnson & Johnson's announcement, ICONIC-ASCEND is a randomized, double-blind, placebo-controlled Phase 3 study, described by the company as the first head-to-head study of an oral pill against an injectable biologic, ustekinumab, in moderate-to-severe plaque psoriasis. The company reported that the trial met both co-primary endpoints versus placebo.

Johnson & Johnson attributed a PASI 90 response, meaning at least 90% improvement in the Psoriasis Area and Severity Index, to 55.2% of ICOTYDE patients versus 3.6% on placebo. It reported IGA 0/1, clear or minimal disease on a five-point scale, at 70.4% versus 9.5%. These are company-reported trial results, not an independent assessment.

How the Oral IL-23 Receptor Blocker Works

Johnson & Johnson describes ICOTYDE as a targeted oral peptide designed to block the IL-23 receptor, which the company links to the inflammatory response in moderate-to-severe plaque psoriasis. Its announcement describes inhibition of IL-23 signaling in human T cells, while stating that the clinical significance of those laboratory findings is unknown.

According to the prescribing information cited by Johnson & Johnson, patients take the medicine upon waking with water on an empty stomach before eating. The drug was jointly discovered and is being developed under a license and collaboration agreement with Protagonist. Those development arrangements are separate from the clinical comparisons reported in ICONIC-ASCEND.

Secondary Endpoints: Non-Inferiority, Not Superiority

Johnson & Johnson reported that across all multiplicity-controlled key secondary endpoints, ICOTYDE achieved non-inferiority to ustekinumab at Week 28, with numerically higher response rates on skin clearance measures IGA 0, IGA 0/1, PASI 90 and PASI 100 in both systemic-naive and biologic-experienced patients.

The company's notes state that statistical superiority was not demonstrated across those key secondary endpoints. Numerical advantages should therefore not be described as proven superiority. Readers assessing the announcement should keep that comparison separate from the placebo-controlled co-primary results rather than treating every reported skin-clearance outcome as evidence of the same kind.

Safety Profile as Reported by the Company

Johnson & Johnson said the safety profile of ICOTYDE was consistent with previous studies, with no new safety signals identified. That company characterization should be read alongside the medicine's safety information rather than interpreted as an absence of risk. Assessing reported efficacy and assessing treatment precautions are separate clinical considerations.

The safety information warns that ICOTYDE may lower the ability to fight infections and increase infection risk. It says providers may check for infections and tuberculosis before treatment, and should monitor for tuberculosis symptoms during and after treatment. Listed common side effects include headache, nausea, cough, fungal infection and tiredness. Live vaccines should be avoided during treatment, according to the label.

What This Means for Practitioners

The announcement describes existing approvals alongside the trial findings. ICOTYDE is approved in the U.S. for moderate-to-severe plaque psoriasis in adults and pediatric patients 12 and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy, and in Europe, Japan and China for adults and adolescents with psoriasis.

Johnson & Johnson frames the data as support for first-line systemic use. Clinicians reviewing that position should distinguish placebo-controlled efficacy from the non-inferiority comparison, consider infection precautions and consult the prescribing information. The announcement should inform professional interpretation of the evidence, not be treated as a recommendation to change any individual's treatment plan.